PBPatricia W. Bedard

Patricia W. Bedard

*This is an algorithmically generated author record based on publicly available information.

Patricia W. Bedard has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ander Vergara

    Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain

    1 shared publication
  • Audrey Izuhara

    Departments of Physiology and Neuroscience, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA

    1 shared publication
  • Carmen Llorens-Cebrià

    Clinical Biochemistry Department, Vall d'Hebrón University Hospital, Clinical Biochemistry, drug delivery and Therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebrón Barcelona Hospital Campus, 08035, Barcelona, Spain

    1 shared publication
  • Conxita Jacobs-Cachá

    Clinical Biochemistry, Drug Delivery and Therapy Research Group, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain

    1 shared publication
  • Francisco J. Álvarez

    Travere Therapeutics, Inc., San Diego, CA 92130, USA

    1 shared publication
  • Georgina Gyarmati

    University of Southern California

    1 shared publication

Latest Publications

  • Open Access

    Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS

    by Georgina Gyarmati, Urvi Nikhil Shroff, Audrey Izuhara, Sachin Deepak, Radko Komers, Patricia W. Bedard, Janos Peti-Peterdi

    Dual endothelin-1 (ET-1) and angiotensin II (AngII) receptor antagonism with sparsentan has strong antiproteinuric actions via multiple potential mechanisms that are more pronounced, or additive, compared with current standard of care using angiotensin receptor blockers (ARBs). Considering the many actions of ET-1 and AngII on multiple cell types, this study aimed to determine glomeruloprotective mechanisms of sparsentan compared to the ARB losartan by direct visualization of its effects in the intact kidney in focal segmental glomerulosclerosis (FSGS) using intravital multiphoton microscopy. In both healthy and FSGS models, sparsentan treatment increased afferent/efferent arteriole diameters; increased or preserved blood flow and single-nephron glomerular filtration rate; attenuated acute ET-1 and AngII–induced increases in podocyte calcium; reduced proteinuria; preserved podocyte number; increased both endothelial and renin lineage cells and clones in vasculature, glomeruli, and tubules; restored glomerular endothelial glycocalyx; and attenuated mitochondrial stress and immune cell homing. These effects were either not observed or of smaller magnitude with losartan. The pleiotropic nephroprotective effects of sparsentan included improved hemodynamics, podocyte and endothelial cell functions, and tissue repair. Compared with losartan, sparsentan was more effective in the sustained preservation of kidney structure and function, which underscores the importance of the ET-1 component in FSGS pathogenesis and therapy.


  • Open Access

    Endothelin Receptor Antagonists in Kidney Disease

    by Irene Martínez-Díaz, Nerea Martos, Carmen Llorens-Cebrià, Francisco J. Álvarez, Patricia W. Bedard, Ander Vergara, Conxita Jacobs-Cachá, Maria José Soler

    Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as hyperfiltration, podocyte damage, proteinuria and, eventually, GFR decline. Therefore, endothelin receptor antagonists (ERAs) have been proposed as a therapeutic strategy to reduce proteinuria and slow the progression of kidney disease. Preclinical and clinical evidence has revealed that the administration of ERAs reduces kidney fibrosis, inflammation and proteinuria. Currently, the efficacy of many ERAs to treat kidney disease is being tested in randomized controlled trials; however, some of these, such as avosentan and atrasentan, were not commercialized due to the adverse events related to their use. Therefore, to take advantage of the protective properties of the ERAs, the use of ETA receptor-specific antagonists and/or combining them with sodium-glucose cotransporter 2 inhibitors (SGLT2i) has been proposed to prevent oedemas, the main ERAs-related deleterious effect. The use of a dual angiotensin-II type 1/endothelin receptor blocker (sparsentan) is also being evaluated to treat kidney disease. Here, we reviewed the main ERAs developed and the preclinical and clinical evidence of their kidney-protective effects. Additionally, we provided an overview of new strategies that have been proposed to integrate ERAs in kidney disease treatment.